Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 337 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma December 11, 2024 Data from a Large Cohort of Patients with mRCC Demonstrate the... September 21, 2020 Spurred by Survivors, Researchers Are Revisiting Cancer Drug Doses June 5, 2024 Lung Adenocarcinoma with Mucinous Histology December 16, 2024 Load more HOT NEWS Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors Welcome to Caring Connections The EPA’s Limitations On This Toxic Pesticide Put Children At Risk... The Largest Randomised Study to Date Points to Low Ipsilateral Breast...
